Amicus Therapeutics, Inc. (NASDAQ:FOLD) Receives Consensus Recommendation of “Hold” from Analysts

Amicus Therapeutics, Inc. (NASDAQ:FOLD) has received an average recommendation of “Hold” from the thirteen research firms that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and three have issued a buy rating on the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $15.3889.

FOLD has been the subject of a number of recent research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Amicus Therapeutics in a research note on Monday, December 29th. Needham & Company LLC downgraded shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, December 19th. TD Cowen cut shares of Amicus Therapeutics from a “buy” rating to a “hold” rating and set a $14.50 price objective for the company. in a research note on Monday, December 22nd. Guggenheim downgraded shares of Amicus Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, January 5th. Finally, Leerink Partners lowered shares of Amicus Therapeutics from an “outperform” rating to a “market perform” rating and decreased their target price for the company from $17.00 to $14.50 in a research report on Monday, December 29th.

Amicus Therapeutics Price Performance

FOLD stock opened at $14.37 on Monday. Amicus Therapeutics has a twelve month low of $5.51 and a twelve month high of $14.39. The company has a market cap of $4.51 billion, a PE ratio of -179.63 and a beta of 0.43. The business’s 50-day simple moving average is $14.32 and its 200 day simple moving average is $11.20. The company has a quick ratio of 1.88, a current ratio of 2.84 and a debt-to-equity ratio of 1.43.

Amicus Therapeutics (NASDAQ:FOLD) last posted its quarterly earnings results on Friday, February 20th. The biopharmaceutical company reported $0.10 EPS for the quarter, missing the consensus estimate of $0.13 by ($0.03). Amicus Therapeutics had a negative net margin of 4.27% and a positive return on equity of 4.15%. The firm had revenue of $185.21 million during the quarter, compared to analyst estimates of $185.00 million. During the same period last year, the company earned $0.09 EPS. The company’s revenue was up 23.7% on a year-over-year basis. On average, research analysts anticipate that Amicus Therapeutics will post 0.15 earnings per share for the current year.

Insider Transactions at Amicus Therapeutics

In other Amicus Therapeutics news, insider David Michael Clark sold 25,642 shares of Amicus Therapeutics stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $14.17, for a total transaction of $363,347.14. Following the sale, the insider directly owned 245,690 shares of the company’s stock, valued at approximately $3,481,427.30. The trade was a 9.45% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Bradley L. Campbell sold 75,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $14.31, for a total value of $1,073,250.00. Following the completion of the sale, the chief executive officer owned 1,021,180 shares in the company, valued at approximately $14,613,085.80. This represents a 6.84% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 123,142 shares of company stock valued at $1,759,472. Corporate insiders own 2.20% of the company’s stock.

Institutional Trading of Amicus Therapeutics

Large investors have recently bought and sold shares of the stock. HBK Investments L P bought a new position in shares of Amicus Therapeutics during the fourth quarter valued at $217,160,000. Pentwater Capital Management LP bought a new stake in shares of Amicus Therapeutics in the 4th quarter worth about $163,760,000. Vestal Point Capital LP grew its holdings in shares of Amicus Therapeutics by 178.4% in the 2nd quarter. Vestal Point Capital LP now owns 11,900,000 shares of the biopharmaceutical company’s stock worth $68,187,000 after purchasing an additional 7,625,000 shares during the last quarter. Soros Fund Management LLC acquired a new stake in shares of Amicus Therapeutics during the 4th quarter worth about $71,200,000. Finally, UBS Group AG increased its position in shares of Amicus Therapeutics by 240.5% during the 4th quarter. UBS Group AG now owns 5,893,288 shares of the biopharmaceutical company’s stock worth $83,920,000 after purchasing an additional 4,162,433 shares in the last quarter.

Amicus Therapeutics Company Profile

Amicus Therapeutics (NASDAQ:FOLD) is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for rare and orphan diseases. The company specializes in pharmacological chaperones and gene therapy approaches designed to address the underlying causes of lysosomal storage disorders. Its proprietary technology platform integrates structure‐based drug design with precision medicine to identify small molecules that stabilize misfolded proteins and restore cellular function.

The company’s lead marketed product, Galafold (migalastat), is an oral pharmacological chaperone approved in the United States, European Union and other territories for the treatment of Fabry disease in patients with amenable genetic variants.